A股異動 | 新天藥業漲逾6% 回購股份疊加獲批進行藥物臨牀研究
格隆匯12月3日丨新天藥業(002873.SZ)現漲6.69%,報15.79元,暫成交2303萬元,最新總市值18億。公司昨日公告稱,截至2019年11月30日公司已累計回購了46.3萬股,佔公司總股本的0.4%,回購價16.5元至14.65元/股。公告還顯示,貴州省藥品監督管理局同樣公司白朮配方顆粒等151個品種進入臨牀研究。有利於加快公司完善中藥產業鏈佈局、豐富產品結構、滿足市場需求並進一步擴大品牌效應及市場份額,構建公司新的利潤增長點,實現公司業績的進一步提升。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.